Can long-term COVID-19 vaccination be improved by serological surveillance?: a modeling study for Mozambique

Seroprevalence provides an estimate of the population-level susceptibility to infection. In this study, we used a transmission model to examine the potential of using serological surveillance to inform the timing of COVID-19 boosters in Mozambique. We simulated using population-level seroprevalence thresholds as an estimate of the risk of outbreaks to trigger the timing of re-vaccination campaigns among older adults. We compare this approach to a strategy of re-vaccination at fixed time intervals. Vaccinating older adults each time the seroprevalence among older adults falls below 50% and 80% resulted in medians of 20% and 71% reduction in deaths, respectively, and number-needed-to-vaccinate to avert one death (NNT) of 1,499 (2.5th-97.5th centile:1,252-1,905) and 3,151 (2,943-3,429), respectively. In comparison, biennial and annual re-vaccination of older adults resulted in medians of 35% and 52% deaths averted, respectively, and NNTs of 1,443 (1,223-1,733) and 1,941 (1,805-2,112), respectively. We conducted sensitivity analysis over a range of antibody waning rates and epidemic scenarios and found that re-vaccination trigger thresholds of 50-60% seroprevalence are most likely to be efficient compared to fixed-time strategies. However, given marginal gains in efficiency even in the best-case scenarios, our results favor the use of simpler fixed-time strategies for long-term control of SARS-CoV-2.

[1]  Andrea A. Berry,et al.  Persistence of antibody responses to COVID-19 vaccines among participants in the COVID-19 Community Research Partnership. , 2023, Vaccine: X.

[2]  B. Lopman,et al.  Serological Studies and the Value of Information. , 2023, American journal of public health.

[3]  Andrea A. Berry,et al.  Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021 , 2023, Vaccine.

[4]  A. Ghani Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling study , 2023, medRxiv.

[5]  G. Hather,et al.  The impact of vaccination frequency on COVID-19 public health outcomes: A model-based analysis , 2023, medRxiv.

[6]  Zahra A. Premji,et al.  Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression , 2023, The Lancet Infectious Diseases.

[7]  M. Exline,et al.  Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. , 2022, MMWR. Morbidity and mortality weekly report.

[8]  A. Azman,et al.  Building an integrated serosurveillance platform to inform public health interventions: Insights from an experts’ meeting on serum biomarkers , 2022, PLoS neglected tropical diseases.

[9]  H. Zar,et al.  Natural and hybrid immunity following four COVID-19 waves: A prospective cohort study of mothers in South Africa , 2022, eClinicalMedicine.

[10]  D. Skowronski,et al.  Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study , 2022, The Lancet Infectious Diseases.

[11]  Quentin J. Leclerc,et al.  Modelling the medium-term dynamics of SARS-CoV-2 transmission in England in the Omicron era , 2022, Nature Communications.

[12]  E. Karlson,et al.  Longitudinal SARS-CoV-2 Nucleocapsid Antibody Kinetics, Seroreversion, and Implications for Seroepidemiologic Studies , 2022, Emerging infectious diseases.

[13]  K. Lythgoe,et al.  SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection , 2022, Nature Communications.

[14]  I. Jani,et al.  Prevalence of SARS-CoV-2 antibodies in the Mozambican population: a cross-sectional Serologic study in three cities, July-August 2020 , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Gheyath K Nasrallah,et al.  Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.

[16]  C. Viboud,et al.  Projecting the SARS-CoV-2 transition from pandemicity to endemicity: Epidemiological and immunological considerations , 2022, PLoS pathogens.

[17]  O. Watson,et al.  Global impact of the first year of COVID-19 vaccination: a mathematical modelling study , 2022, The Lancet Infectious Diseases.

[18]  E. Boerwinkle,et al.  Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey , 2022, The Journal of infectious diseases.

[19]  K. Bibbins-Domingo,et al.  COVID-19 Vaccination and Estimated Public Health Impact in California , 2022, JAMA network open.

[20]  N. Dean,et al.  The changing epidemiology of SARS-CoV-2 , 2022, Science.

[21]  P. Diggle,et al.  Population antibody responses following COVID-19 vaccination in 212,102 individuals , 2022, Nature communications.

[22]  A. Charlett,et al.  Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection , 2022, The New England journal of medicine.

[23]  C. M. Saad-Roy,et al.  Modelling vaccination strategies for COVID-19 , 2022, Nature Reviews Immunology.

[24]  K. Brown,et al.  Protective effect of a first SARS-CoV-2 infection from reinfection: a matched retrospective cohort study using PCR testing data in England , 2022, Epidemiology and Infection.

[25]  H. Gómez-Dantés,et al.  The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries , 2021, Viruses.

[26]  Han Liu,et al.  Cost-effectiveness analysis of BNT162b2 COVID-19 booster vaccination in the United States , 2021, International Journal of Infectious Diseases.

[27]  Jue Liu,et al.  Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis , 2021, Infectious Diseases of Poverty.

[28]  K. Lythgoe,et al.  Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, Nature Communications.

[29]  S. Truelove,et al.  A systematic review of COVID-19 vaccine efficacy and effectiveness against SARS-CoV-2 infection and disease , 2021, medRxiv.

[30]  M. Halloran,et al.  Transition to endemicity: Understanding COVID-19 , 2021, Immunity.

[31]  William F. Fadel,et al.  Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings , 2021, The New England journal of medicine.

[32]  M. Abu-Farha,et al.  Previous COVID-19 Infection and Antibody Levels After Vaccination , 2021, Frontiers in Public Health.

[33]  G. Ayenigbara,et al.  The challenges to a successful COVID-19 vaccination programme in Africa. , 2021, Germs.

[34]  D. Stuart,et al.  Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom , 2021, Nature Microbiology.

[35]  E. Holmes,et al.  After the pandemic: perspectives on the future trajectory of COVID-19 , 2021, Nature.

[36]  Paul J. Birrell,et al.  Anti-spike antibody response to natural SARS-CoV-2 infection in the general population , 2021, medRxiv.

[37]  J. Nkengasong,et al.  COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead , 2021, Immunity.

[38]  A. Hayward,et al.  Spike-antibody waning after second dose of BNT162b2 or ChAdOx1 , 2021, The Lancet.

[39]  S. Pei,et al.  Role of meteorological factors in the transmission of SARS-CoV-2 in the United States , 2021, Nature Communications.

[40]  Tangchun Wu,et al.  Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection , 2021, Cellular & Molecular Immunology.

[41]  M. V. Van Kerkhove,et al.  Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021 , 2021, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[42]  M. Davenport,et al.  Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection , 2021, Nature Medicine.

[43]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[44]  Weizhong Yang,et al.  Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study , 2021, The Lancet.

[45]  Y. Ge,et al.  Modeling the use of SARS-CoV-2 vaccination to safely relax non-pharmaceutical interventions , 2021, medRxiv.

[46]  12,et al.  SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay , 2021, medRxiv.

[47]  M. Van Ranst,et al.  Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection , 2021, Journal of Clinical Virology.

[48]  C. M. Saad-Roy,et al.  Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes , 2021, medRxiv.

[49]  O. Bjørnstad,et al.  Immunological characteristics govern the transition of COVID-19 to endemicity , 2021, Science.

[50]  M. Veldhoen,et al.  Endemic SARS-CoV-2 will maintain post-pandemic immunity , 2021, Nature Reviews Immunology.

[51]  Yi Bai,et al.  SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans , 2020, Research square.

[52]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[53]  K. Koelle,et al.  Indirect benefits are a crucial consideration when evaluating SARS-CoV-2 vaccine candidates , 2020, Nature Medicine.

[54]  Z. Livneh,et al.  Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation , 2020, EClinicalMedicine.

[55]  P. Kellam,et al.  Antibody response to SARS-CoV-2 infection in humans: A systematic review , 2020, medRxiv.

[56]  F. Miralles-Wilhelm,et al.  Temperature, Humidity, and Latitude Analysis to Estimate Potential Spread and Seasonality of Coronavirus Disease 2019 (COVID-19) , 2020, JAMA network open.

[57]  M. Roser,et al.  Coronavirus Pandemic (COVID-19) , 2020 .

[58]  A. Azman,et al.  Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward , 2020, Science Immunology.

[59]  F. Yu,et al.  Serology characteristics of SARS-CoV-2 infection since exposure and post symptom onset , 2020, European Respiratory Journal.

[60]  Rachel E. Baker,et al.  Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic , 2020, Science.

[61]  Yonatan H. Grad,et al.  Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period , 2020, Science.

[62]  J. Rocklöv,et al.  The reproductive number of COVID-19 is higher compared to SARS coronavirus , 2020, Journal of travel medicine.

[63]  J. Lessler,et al.  Impact on Epidemic Measles of Vaccination Campaigns Triggered by Disease Outbreaks or Serosurveys: A Modeling Study , 2016, PLoS medicine.

[64]  O Diekmann,et al.  The construction of next-generation matrices for compartmental epidemic models , 2010, Journal of The Royal Society Interface.

[65]  Pejman Rohani,et al.  Appropriate Models for the Management of Infectious Diseases , 2005, PLoS medicine.

[66]  M. Stein Large sample properties of simulations using latin hypercube sampling , 1987 .